Arcus Biosciences (RCUS) Non-Current Deffered Revenue (2017 - 2026)
Arcus Biosciences (RCUS) posted quarterly Non-Current Deffered Revenue of $45.0 million for Q1 2026, down 79.45% year-over-year from $219.0 million in Q1 2025, and up 4.65% quarter-over-quarter from $43.0 million in Q4 2025.
Arcus Biosciences (RCUS) Non-Current Deffered Revenue (2017 - 2026) Analysis & Trends
Arcus Biosciences' Non-Current Deffered Revenue history runs 10 years deep, the most recent figure standing at $45.0 million for Q1 2026.
- In Q1 2026, Non-Current Deffered Revenue fell 79.45% year-over-year to $45.0 million; the TTM figure through Mar 2026 stood at $45.0 million (down 79.45% YoY), while the FY2025 annual figure was $43.0 million, down 81.62% from the prior year.
- Non-Current Deffered Revenue for Q1 2026 stood at $45.0 million, up from $43.0 million in the prior quarter.
- The five-year high for Non-Current Deffered Revenue was $456.9 million in Q1 2022, with the low at $43.0 million in Q4 2025.
- The 5-year median for Non-Current Deffered Revenue is $289.0 million (2024), against an average of $253.9 million.
- The sharpest annual moves came in 2022 and 2025: Non-Current Deffered Revenue jumped 313.19% in 2022, then slumped 81.66% in 2025.
- Arcus Biosciences' Non-Current Deffered Revenue stood at $355.0 million in 2022, then dropped by 13.52% to $307.0 million in 2023, then dropped by 23.78% to $234.0 million in 2024, then tumbled by 81.62% to $43.0 million in 2025, then grew by 4.65% to $45.0 million in 2026.
- Business Quant data shows RCUS's Non-Current Deffered Revenue at $45.0 million in Q1 2026, $43.0 million in Q4 2025, and $53.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 220.40 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Arcus Biosciences | 3.74 Bn | 3.04 Bn | - | 37.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 37.00 Mn |
| Mar 31, 2026 | 45.00 Mn |
| Dec 31, 2025 | 43.00 Mn |
| Sep 30, 2025 | 53.00 Mn |
| Jun 30, 2025 | 60.00 Mn |
| Mar 31, 2025 | 219.00 Mn |
| Dec 31, 2024 | 234.00 Mn |
| Sep 30, 2024 | 289.00 Mn |
| Jun 30, 2024 | 214.00 Mn |
| Mar 31, 2024 | 242.00 Mn |
| Dec 31, 2023 | 307.00 Mn |
| Sep 30, 2023 | 326.00 Mn |
| Jun 30, 2023 | 330.00 Mn |
| Mar 31, 2023 | 330.00 Mn |
| Dec 31, 2022 | 355.00 Mn |
| Sep 30, 2022 | 382.58 Mn |
| Jun 30, 2022 | 429.34 Mn |
| Mar 31, 2022 | 456.91 Mn |
| Dec 31, 2021 | 462.00 Mn |
| Sep 30, 2021 | 94.68 Mn |